OncoMatch/Clinical Trials/NCT07095517
Pathways, Risk Factors, and mOleculeS to Prevent Early-onset Colorectal Tumors
Is NCT07095517 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Tirzepatide for colorectal cancer prevention.
Treatment: Tirzepatide — This research study is an open-label Phase 1 Exploratory/Pilot clinical trial to measure the effects of the incretin mimetic, tirzepatide, on tissue, urine, blood, and microbiome biomarkers associated with colorectal cancer risk and to understand the feasibility of this precision prevention trial approach for a future larger study.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Prior therapy
Must have received:
Underwent a screening or surveillance colonoscopy within the prior 9 months
Cannot have received: incretin mimetic therapy
Participants who have ever taken incretin mimetic therapies
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Massachusetts General Hospital Cancer Center · Boston, Massachusetts
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify